Source MDx, Pfizer to ID Biomarkers for Cancer and Inflammatory Rx Response | GenomeWeb
NEW YORK (GenomeWeb News) — Molecular diagnostics company Source MDx today said it will work with Pfizer to uncover biomarkers linked to response and resistance to certain of the drug giant’s cancer and inflammatory candidate compounds.
 
As part of the multi-year alliance, the firms will use genomic and RNA transcription profiling to identify inflammation and cancer-related biomarkers in whole blood and circulating rare cells.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.